Skip to main content
Top
Published in: Clinical & Experimental Metastasis 5/2011

Open Access 01-06-2011 | Research Paper

Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors

Authors: Teodora Evgenieva Goranova, Masayuki Ohue, Yutaro Shimoharu, Kikuya Kato

Published in: Clinical & Experimental Metastasis | Issue 5/2011

Login to get access

Abstract

Intratumor heterogeneity—heterogeneity of cancer cells within a single tumor—is considered one of the most problematic factors of treatment. Genetic heterogeneity, such as in somatic mutations and chromosome aberrations, is a common characteristic of human solid tumors and is probably the basis of biological heterogeneity. Using mutations in APC, TP53 and KRAS as markers to identify distinct colorectal cancer subpopulations, we analyzed a total of 42 primary colorectal cancer tissues and six paired liver metastases with multipoint microsampling, which enabled analysis of mutation patterns and allelic imbalances with a resolution of 0.01 mm2 (about 200 cells). There was usually more than one subpopulation in each primary tumor. Only two of 15 (13.3%) cases with three gene mutations and eight of 27 (29.6%) cases with two gene mutations had a single subpopulation. Cells with mutations in all of the examined genes usually constituted the major population. Multipoint microsampling of six primary and metastatic tumor pairs revealed that the majority of discrepancies in mutation patterns found with the bulk tissue analysis were due to loss of subpopulations in the metastatic tissues. In addition, multipoint microsampling uncovered substantial changes in subpopulations that were not detected with bulk tissue analysis. Specifically, the proportion of KRAS mutation-negative subpopulations increased in the metastatic tumors of four cases. Because KRAS mutation status is linked to cetuximab/panitumumab efficacy, subpopulation dynamics could lead to differences in response to cetuximab/panitumumab in primary versus metastatic tumors.
Appendix
Available only for authorised users
Literature
1.
go back to reference Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8(10):755–768PubMedCrossRef Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8(10):755–768PubMedCrossRef
2.
go back to reference Baisse B, Bouzourene H, Saraga EP et al (2001) Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma. Int J Cancer 93(3):346–352PubMedCrossRef Baisse B, Bouzourene H, Saraga EP et al (2001) Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma. Int J Cancer 93(3):346–352PubMedCrossRef
3.
go back to reference Barnetson R, Jass J, Tse R et al (2000) Mutations associated with microsatellite unstable colorectal carcinomas exhibit widespread intratumoral heterogeneity. Genes Chromosomes Cancer 29(2):130–136PubMedCrossRef Barnetson R, Jass J, Tse R et al (2000) Mutations associated with microsatellite unstable colorectal carcinomas exhibit widespread intratumoral heterogeneity. Genes Chromosomes Cancer 29(2):130–136PubMedCrossRef
4.
go back to reference Giaretti W, Rapallo A, Sciutto A et al (2000) Intratumor heterogeneity of k-ras and p53 mutations among human colorectal adenomas containing early cancer. Anal Cell Pathol 21(2):49–57PubMed Giaretti W, Rapallo A, Sciutto A et al (2000) Intratumor heterogeneity of k-ras and p53 mutations among human colorectal adenomas containing early cancer. Anal Cell Pathol 21(2):49–57PubMed
5.
go back to reference Gonzalez-Garcia I, Sole RV, Costa J (2002) Metapopulation dynamics and spatial heterogeneity in cancer. Proc Natl Acad Sci USA 99(20):13085–13089PubMedCrossRef Gonzalez-Garcia I, Sole RV, Costa J (2002) Metapopulation dynamics and spatial heterogeneity in cancer. Proc Natl Acad Sci USA 99(20):13085–13089PubMedCrossRef
6.
go back to reference Konishi N, Hiasa Y, Matsuda H et al (1995) Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. Am J Pathol 147(4):1112–1122PubMed Konishi N, Hiasa Y, Matsuda H et al (1995) Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. Am J Pathol 147(4):1112–1122PubMed
7.
go back to reference Losi L, Baisse B, Bouzourene H et al (2005) Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis 26(5):916–922PubMedCrossRef Losi L, Baisse B, Bouzourene H et al (2005) Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis 26(5):916–922PubMedCrossRef
8.
go back to reference Lyng H, Beigi M, Svendsrud DH et al (2004) Intratumor chromosomal heterogeneity in advanced carcinomas of the uterine cervix. Int J Cancer 111(3):358–366PubMedCrossRef Lyng H, Beigi M, Svendsrud DH et al (2004) Intratumor chromosomal heterogeneity in advanced carcinomas of the uterine cervix. Int J Cancer 111(3):358–366PubMedCrossRef
9.
go back to reference Samowitz WS, Slattery ML (1999) Regional reproducibility of microsatellite instability in sporadic colorectal cancer. Genes Chromosomes Cancer 26(2):106–114PubMedCrossRef Samowitz WS, Slattery ML (1999) Regional reproducibility of microsatellite instability in sporadic colorectal cancer. Genes Chromosomes Cancer 26(2):106–114PubMedCrossRef
10.
go back to reference Takeshima Y, Amatya VJ, Daimaru Y et al (2001) Heterogeneous genetic alterations in ovarian mucinous tumors: application and usefulness of laser capture microdissection. Hum Pathol 32(11):1203–1208PubMedCrossRef Takeshima Y, Amatya VJ, Daimaru Y et al (2001) Heterogeneous genetic alterations in ovarian mucinous tumors: application and usefulness of laser capture microdissection. Hum Pathol 32(11):1203–1208PubMedCrossRef
11.
go back to reference Taniguchi K, Okami J, Kodama K et al (2008) Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 99(5):929–935PubMedCrossRef Taniguchi K, Okami J, Kodama K et al (2008) Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 99(5):929–935PubMedCrossRef
12.
go back to reference Marusyk A, Polyak K (2010) Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 1805(1):105–117PubMed Marusyk A, Polyak K (2010) Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 1805(1):105–117PubMed
13.
14.
go back to reference Goranova TE, Ohue M, Kato K (2009) Putative precursor cancer cells in human colorectal cancer tissue. Int J Clin Exp Pathol 2(2):154–162PubMed Goranova TE, Ohue M, Kato K (2009) Putative precursor cancer cells in human colorectal cancer tissue. Int J Clin Exp Pathol 2(2):154–162PubMed
15.
go back to reference Campbell PJ, Yachida S, Mudie LJ et al (2010) The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467(7319):1109–1113PubMedCrossRef Campbell PJ, Yachida S, Mudie LJ et al (2010) The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467(7319):1109–1113PubMedCrossRef
16.
go back to reference De Roock W, Piessevaux H, De Schutter J et al (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19(3):508–515PubMedCrossRef De Roock W, Piessevaux H, De Schutter J et al (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19(3):508–515PubMedCrossRef
17.
go back to reference Di Fiore F, Blanchard F, Charbonnier F et al (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96(8):1166–1169PubMedCrossRef Di Fiore F, Blanchard F, Charbonnier F et al (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96(8):1166–1169PubMedCrossRef
18.
go back to reference Hecht JR, Patnaik A, Berlin J et al (2007) Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 110(5):980–988PubMedCrossRef Hecht JR, Patnaik A, Berlin J et al (2007) Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 110(5):980–988PubMedCrossRef
19.
go back to reference Khambata-Ford S, Garrett CR, Meropol NJ et al (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25(22):3230–3237PubMedCrossRef Khambata-Ford S, Garrett CR, Meropol NJ et al (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25(22):3230–3237PubMedCrossRef
20.
go back to reference Lievre A, Bachet JB, Boige V et al (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26(3):374–379PubMedCrossRef Lievre A, Bachet JB, Boige V et al (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26(3):374–379PubMedCrossRef
21.
go back to reference Lievre A, Bachet JB, Le Corre D et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66(8):3992–3995PubMedCrossRef Lievre A, Bachet JB, Le Corre D et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66(8):3992–3995PubMedCrossRef
22.
go back to reference Italiano A, Hostein I, Soubeyran I et al (2010) KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol 17(5):1429–1434PubMedCrossRef Italiano A, Hostein I, Soubeyran I et al (2010) KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol 17(5):1429–1434PubMedCrossRef
23.
go back to reference Baldus SE, Schaefer KL, Engers R et al (2010) Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16(3):790–799PubMedCrossRef Baldus SE, Schaefer KL, Engers R et al (2010) Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16(3):790–799PubMedCrossRef
Metadata
Title
Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors
Authors
Teodora Evgenieva Goranova
Masayuki Ohue
Yutaro Shimoharu
Kikuya Kato
Publication date
01-06-2011
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 5/2011
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-011-9381-0

Other articles of this Issue 5/2011

Clinical & Experimental Metastasis 5/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine